Week of May 5, 2011: Company and People Notes: Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of May 5, 2011: Company and People Notes: Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Company Notes

GE Healthcare has agreed to acquire Applied Precision, a supplier of cellular imaging technologies for the cell-biology and biomedical research sectors. The acquisition, which is subject to customary closing conditions, including regulatory approvals, is expected to close in the second quarter of 2011.

The biopharmaceutical companies Talceris Biotherapeutics and Griflos have reached a consent agreement with the Federal Trade Commission (FTC) that outlines the conditions necessary for Grifols' acquisition of Talecris to proceed. The consent agreement remains subject to approval by FTC before the transaction can be completed. To meet the terms of the agreement, Grifols has agreed to sell select assets and has entered into certain commercial, lease, and manufacturing agreements with the Italian biopharmaceutical company Kedrion for up to seven years. Under the agreement, Kedrion and Grifols will enter into a contract-manufacturing agreement to fractionate and purify Kedrion's plasma and to deliver intravenous immunoglobulin and albumin under Kedrion's private label, and Factor VIII under the trade name Koate, all of them for sale only in the US. Also, Grifols will sell its Melville, New York, fractionation facility to Kedrion and will manage the facility for up to a four-year lease agreement with Kedrion. Grifolos also will sell to Kedrion Talecris' US FVIII business and two Talecris plasma-collection centers.

The contract development firm Velesco has partnered with Vindonwestech, a stability-storage provider and manufacturer of controlled environment rooms, to expand its formulation-development services.

People Notes

Acura Pharmaceuticals announced the passing of Andrew Reddick on Apr. 28, 2011, following an eight-year tenure as president and CEO; he was 58. Robert Jones has been named as Reddick’s interim replacement.

Gilead Sciences appointed Muzammil M. Mansuri as senior vice-president of research and development strategy and corporate development.

NeurogesX, a biopharmaceutical company, announced CEO Anthony DiTonno will retire by the end of 2011. DiTonno has been CEO of NeurogesX since March 2003.

Savient Pharmaceuticals, a specialty biopharmaceutical company, named Richard Crowley executive vice-president of biopharmaceutical operations. Crowley formerly served as senior vice-president of biopharmaceutical operations for ImClone Systems.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here